Management & Regulatory

New National Health Rules Enhance Privacy for Medicare and PBS Data
Management & Regulatory New National Health Rules Enhance Privacy for Medicare and PBS Data

The introduction of the National Health (Privacy) Rules 2025 marks a significant shift in the privacy settings governing the handling of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) claims information by Australian Government agencies. Taking effect on April 1, 2025,

March 25, 2025
How Is Africa Enhancing Its Health Regulatory Leadership?
Management & Regulatory How Is Africa Enhancing Its Health Regulatory Leadership?

In a groundbreaking initiative aimed at transforming the health regulatory landscape across the African continent, the first African Regulators Leadership Program (ARLP) was convened at the Wits Business School in Johannesburg. This program is designed to elevate the leadership skills and

March 24, 2025
What Are the Top Regulatory Concerns for Hospices by 2025?
Management & Regulatory What Are the Top Regulatory Concerns for Hospices by 2025?

The hospice industry faces significant regulatory challenges that have become more pronounced in recent years, with key concerns including evolving telehealth policies and program integrity issues. These challenges were highlighted by hospice professionals in the 2025 Outlook Survey conducted by

March 21, 2025
How Will the Genomic Data Protection Act Impact Consumers?
Management & Regulatory How Will the Genomic Data Protection Act Impact Consumers?

Ivan Kairatov is a Biopharma expert with extensive knowledge in technology and innovation within the industry and considerable experience in research and development. Today, we discuss the newly introduced Genomic Data Protection Act (GDPA) and its implications. Can you explain the main purpose of

March 19, 2025
Are Clinical Trials Finally Becoming More Inclusive for Women?
Management & Regulatory Are Clinical Trials Finally Becoming More Inclusive for Women?

Clinical trials have long been criticized for their lack of diversity, particularly in the participation of women. Historically, such exclusions have led to significant gaps in medical knowledge and treatment efficacy across genders, resulting in potentially biased outcomes for a substantial

March 18, 2025
Is Sutro Biopharma's Restructuring the Key to Long-Term Survival?
Management & Regulatory Is Sutro Biopharma's Restructuring the Key to Long-Term Survival?

In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin

March 17, 2025
Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later